WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016061142) ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/061142    International Application No.:    PCT/US2015/055390
Publication Date: 21.04.2016 International Filing Date: 13.10.2015
IPC:
A61K 39/395 (2006.01), C07K 16/28 (2006.01), C07K 16/46 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH).
DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue Boston, MA 02215-5440 (US).
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street Cambridge, MA 02138 (US).
FREEMAN, Gordon, James [US/US]; (US) (US only).
SHARPE, Arlene, Helen [US/US]; (US) (US only).
FREY, Gerhard, Johann [DE/US]; (US) (US only).
CHANG, Hwai, Wen [US/US]; (US) (US only).
MATARAZA, Jennifer, Marie [US/US]; (US) (US only).
DRANOFF, Glenn [US/US]; (US) (US only)
Inventors: FREEMAN, Gordon, James; (US).
SHARPE, Arlene, Helen; (US).
FREY, Gerhard, Johann; (US).
CHANG, Hwai, Wen; (US).
MATARAZA, Jennifer, Marie; (US).
DRANOFF, Glenn; (US)
Agent: COLLAZO, Diana M.; (US)
Priority Data:
62/198,545 29.07.2015 US
62/094,847 19.12.2014 US
62/063,852 14.10.2014 US
62/213,076 01.09.2015 US
Title (EN) ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
(FR) MOLÉCULES D'ANTICORPS DE PD-L1 ET LEURS UTILISATIONS
Abstract: front page image
(EN)Antibody molecules that specifically bind to PD-Ll are disclosed. Combination therapies comprising the anti-PD-Ll antibody molecules are also disclosed. The anti-PD-Ll antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
(FR)La présente invention concerne des molécules d'anticorps qui se lient spécifiquement à PD-L1. L'invention concerne également des polythérapies contenant les molécules d'anticorps anti-PD-L1. Les molécules d'anticorps anti-PD-L1 peuvent être utilisées pour traiter, prévenir et/ou diagnostiquer des états ou troubles cancéreux ou infectieux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)